Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
HawkEye 360, a Herndon, Virginia-based space analytics firm, has filed for a U.S. initial public offering seeking up to $416 million and targeting a valuation of as much as $2.42 billion. The company plans to offer 16 million shares at $24 to $26 each and to list on the New York Stock Exchange under the symbol HAWK. The move comes as the IPO market…
Sagimet Biosciences has priced an underwritten offering of 29.17 million Series A common stock shares at $6.00 each, aiming to raise approximately $175 million. The proceeds will fund late-stage clinical trials including a Phase 3 study for denifanstat in moderate to severe acne, advance pipeline candidates through Phase 2 results, and support gene…
Veradermics' stock rose 17% after the company disclosed topline results from its Phase 2/3 Study '302' of VDPHL01 for male pattern hair loss. The extended-release oral minoxidil formulation achieved statistically significant improvements in hair counts and patient- and investigator-reported measures versus placebo, with no treatment-related serious…
SLB combines scale in drilling and production systems with an expanding digital platform. Recent deals in Suriname and Angola validate its geographic diversification and software-led growth, but cyclical capex, regional risks and near-term volatility argue for a disciplined, risk-managed long trade.
Oruka Therapeutics' stock climbed sharply after the company reported positive Week 16 results from the EVERLAST-A Phase 2a trial of ORKA-001 in moderate-to-severe plaque psoriasis. The study met its primary endpoint, with a majority of treated patients achieving complete skin clearance and secondary endpoints showing deep clinical responses. Safety…
Intellia Therapeutics reported that its Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met the primary endpoint and all key secondary endpoints, showing an 87% reduction in hereditary angioedema attacks versus placebo over six months. The single-dose, in vivo gene editing therapy demonstrated favorable safety and tolerability among treated …
Allot Ltd., a global provider of Security-as-a-Service and network intelligence solutions, announced it will release its first quarter 2026 financial results and hold a conference call on May 12, 2026. The company provides cybersecurity and network analytics solutions to service providers and enterprises worldwide.
Wolfe Research reports that energy stocks found buying support after approaching oversold territory last week. The firm highlights the sector's ability to reclaim the 50-day moving average this week as a key test that will help determine whether the move is a short-lived relief rally or the start of a renewed uptrend. A recent washout left more tha…
HBT Financial, Inc. announced first quarter 2026 results with net income of $11.2 million ($0.34 per diluted share) and adjusted net income of $22.6 million ($0.68 per diluted share). The company completed its merger with CNB Bank Shares, Inc. on March 1, 2026, successfully integrating systems. Asset quality remained strong with low nonperforming a…
Top U.S. independent refiners are anticipated to report materially stronger first-quarter results versus a year earlier as supply constraints from the Middle East conflict lifted diesel and jet fuel margins to multi-year highs. The closure of the Strait of Hormuz after the late-February escalation in the region tightened flows of barrels and refine…
Nissan Motor Co. updated its full-year operating forecast, moving from a projected ¥60 billion loss to an expected ¥50 billion profit for the fiscal year ending March 2026. The company announced the revision after markets closed on April 27, attributing the swing mainly to a reversal of provisions tied to U.S. greenhouse gas regulations, alongside …
Youxin Technology Ltd announced it will acquire an 18% equity stake in YATOP Group Limited, a leading TikTok marketing and branding agency, for approximately $10.8 million via share exchange. This strategic investment aims to enhance Youxin's SaaS and PaaS digital commerce ecosystem by integrating YATOP's strong global influencer marketing and e-co…
Purple Biotech announced new preclinical data validating the efficacy of IM1240, its lead CAPTN-3 tri-specific antibody. Generated by Dr. Amir Horowitz's team at Mount Sinai, the data shows IM1240's NKG2A arm significantly enhances anti-tumor activity across multiple resistant patient-derived tumor samples, including PD-1 resistant cancers. The ant…
Ligand Pharmaceuticals announced the acquisition of XOMA Royalty Corporation for approximately $739 million in cash, adding over 120 assets including seven marketed products and significantly expanding its royalty portfolio across multiple therapeutic areas. The acquisition is expected to be immediately accretive to adjusted EPS and has prompted Li…
Aurora Mobile's sub-brand MoonFox Data showcased its sophisticated multi-dimensional alternative data platform at the Neudata Hong Kong Summit, demonstrating how its online, offline, transactional, and sentiment data enable investors to forecast earnings and generate alpha in Chinese markets. MoonFox highlighted its extensive coverage of over 600 l…
Seer, Inc.'s Board of Directors unanimously rejected a revised unsolicited acquisition proposal from the Radoff-JEC Group offering $2.35 per share plus contingent value rights. The Board stated the offer significantly undervalues Seer considering its strong growth potential, proprietary proteomics platform, increasing adoption, and large market opp…
Sagimet Biosciences announced plans to initiate a Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S. starting in the second half of 2026, following positive Phase 3 results reported in China. The company is also advancing its FASN inhibitor pipeline with an ongoing Phase 1 trial of TVB-3567 and is prioritizing dermatology…
Ocular Therapeutix, a biopharmaceutical company focused on retinal disease treatments, has announced its participation in various upcoming scientific and investor conferences in May 2026. The company will present clinical trial results, particularly for its investigational product AXPAXLI (OTX-TKI), currently in Phase 3 trials for wet age-related m…
Intellia Therapeutics has started a rolling submission of a biologics license application to the FDA seeking approval for lonvoguran ziclumeran (lonvo-z), an innovative one-time in vivo CRISPR gene-editing treatment for hereditary angioedema (HAE). Positive topline Phase 3 HAELO trial data indicate that lonvo-z met primary and secondary endpoints, …
Harrow, a Nasdaq-listed ophthalmic disease management company, will release its financial results for Q1 2026 after market close on May 11, followed by a conference call on May 12 to discuss the results and provide a business update.
Cardiff Oncology announced it will host a key opinion leader webinar on April 30, 2026, to discuss data from an investigator-initiated trial showing onvansertib's promising single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The event features Dr. Mrinal Patnaik from Mayo Clinic and aims to highlight onvansertib's potential as…
U.S. Energy Corp. (NASDAQ: USEG) announced a five-year helium sales agreement with an investment-grade global industrial gas company for helium produced at its Big Sky Carbon Hub in Montana. The contract guarantees purchase of 100% of Phase 1 helium production at a fixed plant-gate price of $285 per thousand cubic feet with annual inflation adjustm…
GXO Logistics, the largest pure-play contract logistics provider, announced its partnership with the Arrow McLaren IndyCar Team as an Official Partner for the 110th Running of the Indianapolis 500. GXO branding will be prominently featured on the No. 31 car driven by Ryan Hunter-Reay. This partnership aligns GXO's values of teamwork, precision, and…
Intellia Therapeutics reported positive topline results from its global Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z), a one-time in vivo CRISPR gene editing therapy targeting hereditary angioedema (HAE). The trial met its primary and all key secondary endpoints, showing an 87% reduction in attacks over six months versus placebo, with favo…
Altimmune, Inc. has completed an oversubscribed public offering raising $225 million in gross proceeds to fund its upcoming Phase 3 clinical trial of pemvidutide, a novel therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) and other serious liver diseases. The financing provides cash runway through the anticipated 52-week data…
